Loading
EI
Enhabit, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Aug 2025.
Enhabit, Inc.: what insiders have been doing
Enhabit, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 67 filings signed by 16 insiders.
Only sales appear on the open market, 2 sales in all totalling €49k, filed by 2 insiders. Jolley Julie Diane filed the largest sale, €33k, on 11 March 2026.
With 67 filings in twelve months, the company is more active than the median of 19 filings across the 5,814 companies we follow on the same exchange. Since 2022, the database holds 30 purchases and 2 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 1.06 bn USD and net income of -4.6 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
246
Thresholds
n/a
Buy Volume
€2M
30 ops. · all time
Sell Volume
€49,481
2 ops. · all time
Who traded when
BuySaleJeffrey Bolton2 buys
Collin McQuiddy1 sale
Julie Diane Jolley1 sale
Ryan Solomon1 buy
Stuart M. Mcguigan1 buy
Analyst consensus: bullish or bearish?
Analysts rate Enhabit, Inc. Hold (neutral), based on 5 analysts. Average price target: US$13.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,157 of 24,148 companies
40.6
score / 100
Value48
Quality34
FCF yld9.3%
Earn yld-0.7%
EV/EBITDA15.0x
ROE-0.2%
Gross mgn49%
Net mgn-0.4%
Debt/EBITDA6.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$13.80
Analyst consensus
5 analystsHold
US$13.80Target US$13.80(0%)US$13.80
Income statement
RevenueUS$1.1B
Gross profitUS$519.8M49% margin
EBITDAUS$80.3M8% margin
Net income-US$4.6M-0.3% margin
Valuation
PER (forward)20.9x
P/Book1.3x
Beta0.96
Balance sheet & cash
Market capUS$706.9M
Total debtUS$500M
Free Cash FlowUS$65.8M
Debt / Equity82%
Profitability & ownership
ROE-0.2%
ROA3.1%
% insiders3.7%
% institutions100.6%
Last declaration on 15 May 2026
Declarations246 total
64,605 shares@ US$13.800.13% mcap54.2% of flowCommon StockSEC:0001205444-26-000007:1
34,413 shares@ US$13.800.067% mcap12.9% of flowCommon StockSEC:0001966580-26-000008:2
49,601 shares@ US$13.800.097% mcap18.5% of flowCommon StockSEC:0001966580-26-000008:4
24,072 shares@ US$13.800.047% mcap9.0% of flowCommon StockSEC:0001966580-26-000008:6
48,000 shares@ US$13.800.094% mcap21.7% of flowCommon StockSEC:0001925331-26-000007:1
80,682 shares@ US$13.800.16% mcap36.4% of flowCommon StockSEC:0001925331-26-000007:2
70,338 shares@ US$13.800.14% mcap54.4% of flowCommon StockSEC:0001328255-26-000006:1
60,466 shares@ US$13.800.12% mcap46.6% of flowCommon StockSEC:0001335234-26-000006:1
69,305 shares@ US$13.800.14% mcap50.6% of flowCommon StockSEC:0001653488-26-000006:1
263,237 shares@ US$13.800.52% mcap18.0% of flowCommon StockSEC:0001691132-26-000006:3
340,530 shares@ US$13.800.67% mcap23.2% of flowCommon StockSEC:0001691132-26-000006:5
58,560 shares@ US$13.800.11% mcap21.9% of flowCommon StockSEC:0001966580-26-000008:1
51,148 shares@ US$13.800.10% mcap57.6% of flowCommon StockSEC:0001937414-26-000002:1
73,412 shares@ US$13.800.14% mcap57.1% of flowCommon StockSEC:0001122124-26-000006:1
65,964 shares@ US$13.800.13% mcap4.5% of flowCommon StockSEC:0001691132-26-000006:1
127,129 shares@ US$13.800.25% mcap8.7% of flowCommon StockSEC:0001691132-26-000006:2
15,000 shares@ US$13.800.029% mcap11.5% of flowCommon StockSEC:0001335234-26-000006:0
1,712 shares@ US$13.800.0034% mcap2.7% of flowCommon StockSEC:0001933968-26-000008:0
413,614 shares@ US$13.800.81% mcap28.2% of flowCommon StockSEC:0001691132-26-000006:0
60,247 shares@ US$13.800.12% mcap46.2% of flowCommon StockSEC:0002048471-26-000006:0
45,867 shares@ US$13.800.090% mcap69.0% of flowCommon StockSEC:0001343342-26-000006:0
41,263 shares@ US$13.800.081% mcap15.4% of flowCommon StockSEC:0001966580-26-000008:0
73,591 shares@ US$13.800.14% mcap49.5% of flowCommon StockSEC:0001933957-26-000010:0
11,100 shares@ US$13.800.022% mcap8.1% of flowCommon StockSEC:0001653488-26-000006:0
7,226 shares@ US$13.800.014% mcap5.6% of flowCommon StockSEC:0001122124-26-000006:0
25 of 246 declarations
About Enhabit, Inc.
Enhabit, Inc. is a United States-based healthcare company listed on the NYSE under the ticker EHAB. Headquartered in Dallas, Texas, Enhabit operates in the home health and hospice care market, a segment supported by long-term demographic and reimbursement trends in the U.S. The company was founded in 1998 and became an independent public company on July 1, 2022, following its separation from Encompass Health Corporation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000018/ehab-20251231.htm?utm_source=openai))
Enhabit’s business model is built around two core service lines. Its home health segment provides clinical care delivered in patients’ homes, including recovery support after surgery, disease and injury management, chronic care monitoring, and coordinated therapy services. Its hospice segment focuses on comfort-oriented end-of-life care, offering medical, emotional, and spiritual support to terminally ill patients and their families. Together, these businesses give Enhabit exposure to a broader continuum of home-based care, which is increasingly favored by patients, providers, and payers seeking lower-cost alternatives to inpatient settings. ([enhabit.com](https://www.enhabit.com/about-us/?utm_source=openai))
Read moreShow less
From a geographic standpoint, the company has a nationwide footprint across 34 states. Enhabit emphasizes its broad network of home health and hospice locations, which helps it maintain referral relationships with hospitals, physicians, health plans, and other care partners. The business relies on local clinical teams, operational density, and technology-enabled care delivery to support patient outcomes and service quality at scale. ([enhabit.com](https://www.enhabit.com/about-us/?utm_source=openai))
In competitive terms, Enhabit is positioned as a scaled national provider in a fragmented industry that includes regional agencies, private operators, and larger healthcare systems expanding into home-based care. Its differentiation lies in its focused specialty in home health and hospice, its national reach, and its ability to manage two complementary service lines under one platform. The company also highlights its patient-centric culture and clinical expertise as key parts of its market positioning. ([enhabit.com](https://www.enhabit.com/about-us/?utm_source=openai))
Recent developments have been important for equity investors. In 2025 and again in March 2026, Enhabit reported improving revenue, patient census, and Adjusted EBITDA, alongside efforts to strengthen free cash flow and the balance sheet. Most notably, on January 23, 2026, the company announced a definitive agreement to be acquired by Kinderhook Capital for $13.80 per share in cash, implying an enterprise value of about $1.1 billion. This transaction is the defining near-term corporate event for Enhabit and a major factor for evaluating the stock on the NYSE in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1803737/000180373726000015/q42025enhabitearningsrelea.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
